Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of Hematology Meeting
Intellia Therapeutics to Present at November Healthcare Investor Conferences
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
Intellia Therapeutics Announces Third Quarter 2017 Financial Results
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2017 Earnings
Intellia Therapeutics to Present at October Healthcare Investor Conferences
Intellia Therapeutics Demonstrates Sustained and Durable Genome Editing with CRISPR/Cas9 in One-Year Animal Study
Intellia Therapeutics to Present at Upcoming September Investor Healthcare Conferences
Intellia Therapeutics Announces Second Quarter 2017 Financial Results